Progression-Free Survival Is Meaningful Endpoint For Glioma Trials
Executive Summary
Progression free survival assessed at six months should be considered as a meaningful surrogate endpoint in evaluating primary brain tumor clinical trials for accelerated approval, a panel assembled by FDA agreed
You may also be interested in...
Avastin Advisory Committee To Assess Validity Of Objective Response Rate Endpoint
FDA questions whether imaging improvements in patients with glioblastoma metaforme are sufficient to denote clinical change.
Pediatric Brain Tumor Populations Too Small For Non-Inferiority Trials – Cmte
The heterogeneity of pediatric brain tumors generally precludes the use of non-inferiority trials to support approval, FDA's Pediatric Oncology Subcommittee determined
Pediatric Brain Tumor Populations Too Small For Non-Inferiority Trials – Cmte
The heterogeneity of pediatric brain tumors generally precludes the use of non-inferiority trials to support approval, FDA's Pediatric Oncology Subcommittee determined